Paraneoplastic erythroderma: an insight on the existing data

Plachouri, Kerasia‐Maria; Georgiou, Sophia

doi:10.1111/ijd.14970

Cited by 4 publications

(14 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Less commonly, it can be associated with solid tumors, usually in the late stage of the disease, including colon, prostate, gastric, and lung carcinoma [4][5][6] . Paraneoplastic syndromes can appear before, during or after the tumor diagnosis 1 . In this case it was the first manifestation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Erythroderma as first sign of lung cancer

Lopes¹,

Guimarães²,

Cerqueira³

et al. 2022

PJDV

View full text Add to dashboard Cite

Erythroderma, or generalized exfoliative dermatitis, is a rare inflammatory disorder characterized by generalized erythema, involving more than 90% of the body surface area, accompanied by a variable degree of scaling. It may be the clinical presentation of several cutaneous or systemic diseases and it is frequently challenging to find the underlying cause. Our case focuses on a 76-year-old male patient that was referred to our department due to generalized erythroderma and diffuse alopecia, developing over the last 4 months. He presented with erythematous papules and nodules, some of them covered with sticky scales. Skin biopsy was compatible with drug eruption. Due to an inadequate response to treatment and typical B symptoms, further imagiologic studies were performed. Ultimately he was diagnosed with non-small cell lung cancer. This case shows the need to search for a neoplasm in patients presenting with erythroderma, particularly in the presence of systemic symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Erythroderma may be the clinical presentation of several cutaneous or systemic diseases. However, it is a rare first manifestation of a solid organ malignancy 1,2 .…”

Section: Introductionmentioning

confidence: 99%

Erythroderma as first sign of lung cancer

Lopes¹,

Guimarães²,

Cerqueira³

et al. 2022

PJDV

View full text Add to dashboard Cite

show abstract

“…2 Various studies have demonstrated the incidence of this relatively rare disorder; a study in an Indian population documented incidence around 35 per 100,000 dermatology patients, 3 and a study of a Chinese population with incidence around 13 per 100,000 dermatology patients. 4 The causes of erythroderma include exacerbation of existing/underlying dermatoses (such as psoriasis, atopic dermatitis, pemphigus), cutaneous drug eruptions 5 and malignancy-related erythroderma either from paraneoplastic causes (representing particular cutaneous manifestations of an underlying malignancy without infiltration of malignant cells 6 ) or from primary cutaneous malignancies such as mycosis fungoides, Sézary syndrome and adult T-cell leukaemia/lymphomas. 7 Despite malignancy-related erythroderma constituting only a small fraction of erythroderma cases, 8 clinical implications on diagnosis and surveillance can be profound.…”

Section: Introductionmentioning

confidence: 99%

“…7 Despite malignancy-related erythroderma constituting only a small fraction of erythroderma cases, 8 clinical implications on diagnosis and surveillance can be profound. 5 Current large-scale studies that examine the incidence of malignancy in erythrodermic patients, particularly in Asian cohorts, are scarce. Although existing literature seems to suggest that malignancy-associated erythroderma has a predilection for elderly patients after the sixth decade of life, 5 studies that systematically elucidate for a malignancy cause in erythrodermic patients are lacking.…”

Section: Introductionmentioning

confidence: 99%

“…5 Current large-scale studies that examine the incidence of malignancy in erythrodermic patients, particularly in Asian cohorts, are scarce. Although existing literature seems to suggest that malignancy-associated erythroderma has a predilection for elderly patients after the sixth decade of life, 5 studies that systematically elucidate for a malignancy cause in erythrodermic patients are lacking. This study aims to describe the prevalence of malignancyassociated erythroderma in a single centre where there was concerted effort to systematically offer malignancy screens to all erythroderma patients above the age of 65 years.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Malignancy‐associated generalised exfoliative dermatitis: A retrospective study in a single‐centre Asian cohort

et al. 2023

View full text Add to dashboard Cite

Background Erythroderma is an inflammatory skin condition that causes extensive erythema and skin scaling amounting ≥90% of the body surface area. This retrospective cohort study describes the prevalence of malignancy‐associated erythroderma in a single centre where there was concerted effort to systematically offer malignancy screens to all adult erythroderma patients above the age of 65 years. Methods Clinical charts were reviewed for all adult inpatients and outpatients with erythroderma who attended the National University Hospital (NUH) from 1 July 2019 to 31 December 2021. Data collected included patient demographics, clinical findings, laboratory investigations, disease‐specific investigations such as endoscopic procedures and biopsies, follow‐up duration and mortality data. Results Seventy‐four patients were analysed. The median age of the patients was 73 years old (interquartile range: 59–81 years old). An underlying dermatosis was the most common cause of erythroderma—63 patients having atopic dermatitis/asteatotic eczema or psoriasis. Three patients had erythroderma from drug eruptions, and 1 patient had chronic actinic dermatitis. Four patients had associated malignancies (5.4%). Half of our patients completed further evaluation for malignancy (52.7%). The rest had either declined or were eventually unable to complete the investigations. There was a higher prevalence of associated malignancy (7.8%) in elderly patients above 65 years old. Conclusion When compared to existing literature, our cohort reflects a higher observed occurrence of malignancy in association with erythroderma. As delays in evaluation for underlying malignancy could result in potentially deleterious outcomes, it is prudent to consider systematic screening for malignancy in high‐risk populations such as elderly erythroderma patients.

show abstract